Filing Flows › 8-K events › Surgery Partners
Surgery Partners: entry into a material definitive agreement
Form 8-K filed Nov 9, 2026 · items 1.01, 7.01
Mergers and acquisitionsSurgery Partners and HealthSpan Partners Announce Amended Merger Agreement, Following Receipt of Unsolicited Proposal
What the filing says
On November 8, 2026, Surgery Partners, Inc., a Delaware corporation (the “Company”), entered into Amendment No. 1 to Agreement and Plan of Merger (the “Amendment”) with Spyglass Topco, LLC, a Delaware limited liability company (“Parent”), Spyglass Merger Subsidiary, Inc., a Delaware corporation and a wholly-owned subsi
Read the filing on SEC EDGAR →
What usually followsAcross 23,535 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Surgery Partners at a glance
Surgery Partners, Q2 2026: revenue $849M (+3% year over year), operating margin 12.0%. The chart follows the revenue to costs, profit and cash.
Surgery Partners: every quarter, Q/Q and Y/Y, holders and guidance →
Surgery Partners’s other material 8-Ks
- Oct 26, 2026 — Mergers and acquisitions HealthSpan Partners to Acquire Surgery Partners, Establishing a Leading Outpatient Surgical Care Pla
Other recent mergers and acquisitions
- loanDepot Nov 9, 2026
- Empery Digital Nov 9, 2026
- Strive Nov 9, 2026
- CDT Equity Nov 9, 2026
- Inflection Point Acquisition Corp. VI Nov 9, 2026
- Jasper Therapeutics Nov 9, 2026
- CorMedix Nov 9, 2026
- Somnigroup International Nov 9, 2026
- ContextLogic Holdings Nov 9, 2026
- Heron Therapeutics Nov 9, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.